Search
Displaying 481–490 of 757 for “retinitis clinical trial”
-
Pioneering Delivery Strategies for Blinding Diseases Therapy and Inspiring Women in Science
Beacon StoriesInternational Day of Women and Girls in Science is celebrated globally to recognize the critical role women play in science, technology, engineering, and mathematics. To honor this vital day, the Foundation is thrilled to spotlight Dr. Renee Ryals, PhD, a remarkable scientist at the Casey Eye Institute, Oregon Health & Science University.
-
Disease
In partnership with organizations focused on TED, we provide educational resources and host community events that connect individuals with the broader blind and low vision community. These efforts strengthen support and awareness, while our core mission remains driving research to advance treatments and cures for blinding retinal diseases.
-
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
Research NewsMore than 8,000 people have applied for genetic testing through the Foundation’s program
-
In the Press
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
-
Foundation Fighting Blindness Commits $6.5 Million for New Retinal Disease Research Grants
Foundation NewsNew grants include development of CRISPR/Cas9 gene-editing treatments, new disease models, and a retinal regeneration therapy
-
Information for Newly Diagnosed Patients and their Loved Ones
-
Foundation News
Three-day conference in San Diego will feature retinal science’s leading researchers and clinicians, and focus on the year’s top science and emerging treatments
-
Foundation News
The primary goal of the landmark study, funded by the Foundation, is to provide companies and researchers with disease-progression data and potential clinical trial endpoints to drive therapy development
-
The FDA's Indispensible Role (a guest blog from Dr. Patricia Zilliox)
Research NewsWhile it may not seem obvious, the FDA ultimately drives everything — the researchers and the money. That’s because without FDA approval, you have no treatment, even if you have great research and adequate funding.
